Pavilion Health Today
Supporting healthcare professionals to deliver the best patient care

Interventions to lower blood pressure in secondary stroke prevention

Drs Amit Mistri and Martin Fotherby summarise the evidence regarding blood pressure lowering as a secondary prevention measure.

Stroke is the third most common cause of mortality in the UK and the single most common cause of severe disability. The National Audit Office, in November 20051 highlighted the need for an emergency response to acute stroke, improved access to rehabilitation and support services, and emphasis on primary and secondary prevention measures. With an estimated annual cost of £7bn to the UK, and a new stroke occurring every five minutes in the UK, the burden to patients, carers and society alike is substantial. The societal cost from strokes is 1.5 times that for the expenses for coronary artery disease, which explains the increasing attention towards the management of cerebrovascular disease.

Pharmacological treatment of acute stroke to improve outcome has been disappointing. Thrombolysis is restricted to the first three hours following a stroke, and therefore applicable to only a small proportion of patients at present. Also there has been little success with trials studying neuroprotective agents. Early antiplatelet therapy is associated with significant benefit, although in absolute terms, this benefit is small2. Therefore, initial supportive treatment, followed by rehabilitation and secondary prevention by controlling known risk factors, is the management plan for most patients.

Relationship between BP and stroke

In patients with no prior history of cerebrovascular disease, the linear association between increasing blood pressure (BP) levels and first stroke has been demonstrated convincingly, with the risk of cardiovascular events doubling for every 20mmHg SBP (systolic blood pressure) or 10mmHg DBP (diastolic blood pressure) rise across the range of BP values from 115/75 to 185/115mmHg3. When considering recurrent stroke (beyond the early post-stroke phase), a similar association between achieved BP and stroke incidence was noted across the range of achieved BP (112/72–168/102mmHg), in a post hoc analysis of patients in the PROGRESS study4. Also a retrospective analysis of 2,201 patients in the UK-TIA study showed a strong positive linear relationship between usual BP and stroke risk (hazard ratio more than doubled per 20mmHg rise in SBP and 10mmHg rise in DBP)5.

A ‘J’-shaped relationship has been demonstrated between post-stroke DBP and stroke recurrence, with the nadir at 80–84mmHg6. There was no association with other BP parameters. The results are difficult to interpret with 69 per cent of patients receiving antihypertensive therapy, and the possibility of co-morbid conditions associated with low BP (eg, myocardial infarction) influencing it. It is reassuring that the Leigh Valley Recurrent Stroke Study7 did not reproduce the possible J-shaped association between BP and stroke recurrence. Those with lowest follow-up DBP (

Also, in patients with cerebrovascular disease high SBP (≥140mmHg) is an independent predictor of risk of intracerebral haemorrhage (hazard ratio 2.17, compared to patients with SBP70 per cent, this association is reversed. Aggressive BP reduction would not be advisable for this uncommon group of patients and a carotid revascularisation procedure may be appropriate prior to initiation of antihypertensive therapy. There is no evidence to guide the management of BP in those patients not fit for revascularisation.

Intervention studies

Metanalyses of trials studying antihypertensive therapy as a secondary prevention intervention have shown a significant reduction in recurrent stroke and vascular events (odds ratio for all stroke: 0.72–0.76, cumulative vascular events: 0.77–0.79)9-11. The data has clearly been influenced by the results of more recent large studies with adequate power to detect differences in outcome – PATS12, PROGRESS13 and HOPE14.

How soon after stroke should we start BP treatment?

There is little evidence currently to support or refute early BP lowering intervention (before the first one to two weeks), and this is therefore not advised15, except in compelling situations (sustained extreme BP elevation, coexistent heart failure, aortic dissection, acute myocardial infarction, acute renal failure or as part of guidelines for thrombolysis in early acute ischaemic stroke). In the ACCESS study candesartan given seven days in 342 patients with BP >180/105mmHg resulted in a significant 47.5 per cent reduction in the secondary outcome of all cause, cerebral and cardiovascular mortality in the acute candesartan treatment arm, but with no effect on the primary outcome of death and disability at three months. However, this was a small study in a select group of stroke patients. There is good evidence of the benefits of BP lowering beyond the early post-stroke phase9-11. In neurologically stable patients, initiation of BP lowering therapy can be considered approximately one to two weeks after the onset of stroke. Furthermore, there may be benefit in commencing antihypertensive therapy prior to discharge from hospital to improve compliance. In patients having had a transient ischemic attack (TIA), therapy can be started soon after the event.

At what level of blood pressure should treatment be initiated?

Because of the high overall cardiovascular risk in patients with cerebrovascular disease, hypertensives as well as ‘normotensives’ are likely to benefit from BP reduction. Supporting this recommendation, the PROGRESS study showed patients with any BP level benefited from treatment. In the subgroup classified as nonhypertensive at baseline, BP was lowered from a mean of 136/79mmHg to 128/75mmHg with significant relative reduction in stroke (27 per cent) and major vascular events (24 per cent)13. Therefore patients with SBP>~130 should be offered antihypertensive therapy for reduction of future risk of vascular events.

The applicability of this recommendation to groups that have not been included in the clinical trials (eg, the very elderly and frail) is uncertain, and a pragmatic approach will be required to estimate the risk/benefit ratio (risk = likelihood of side effects of aggressive BP lowering, especially in normotensives, benefit = reduction of subsequent vascular events), until direct evidence is available.

What is the recommended blood pressure target?

The National Clinical Guidelines for stroke16 recommend a target BP of 140/85mmHg, with further reduction employing a PROGRESS type regime. The recently published British Hypertension Society Guidelines and the Joint British Societies guidelines – JBS2 guidelines suggest a lower target BP of 130/80mmHg, as for all patients with hypertensive target organ disease. The American Heart Association guidelines17 mention uncertainty with regards to the absolute BP reduction or target value, and note that benefit has been associated with an average BP reduction of ~10/5mmHg in persons with or without a history of hypertension. A blood pressure target of 130/80mmHg for hypertensives and a BP reduction of 10/5mmHg for normotensives is recommended, if tolerated. It is well documented that cerebral autoregulation is impaired following stroke; however, whether this persists over a longer period is uncertain. There is thus a theoretical possibility that BP reduction may result in reduced cerebral blood flow and its consequences. This explains some clinicians’ reluctance with regards to BP reduction in patients with cerebrovascular disease. However, no detrimental effects were observed in the subgroup with the lowest achieved BP (SBP

What agents should be used?

If there is a compelling indication for early BP lowering, agents that should be avoided include sublingual nifedipine (rapid BP lowering can exacerbate cerebral ischaemia), oral betablockers18 and high dose intravenous nimodipine19, a dihydropyridine calcium channel blocker (worse outcome compared to placebo in randomised trials). Preliminary evidence suggests that ACE inhibitors or ARBs may be the preferred agents, as they shift the cerebral autoregulation curve to the left, and BP lowering can be achieved without significant reduction in cerebral blood flow. Beyond the acute phase, BP lowering drugs associated with significant benefit in placebo controlled secondary stroke prevention trials are summarised in Table 1. It would be reasonable to choose drugs that are cheap and have been associated with significant benefit in clinical trials of relevant patients. Thiazide-type diuretics and ACE inhibitors are recommended first line agents. Further options include ARBs and dihydropyridine CCBs. Other anti-hypertensives may be preferred if they may be beneficial for comorbidities (eg, beta-blockers for IHD).


Are clinical guidelines followed?

All primary and secondary stroke prevention measures are underused. Specifically, attainment of BP targets in the guidelines is seen only in the minority20. The reasons for this are multifactorial, including:

  • patient factors (poor utilisation of preventive therapies in general as opposed to curative therapy; lack of awareness of risk denial; fear; non-compliance);
  • physician factors (lack of clarity as to the lead role in identifying risk factors; initiating treatment; monitoring long-term compliance and attainment of goals specified in guidelines);
  • practice environment (increasing demands on the time of primary and secondary care physicians leading to abbreviation or disregard of preventive intervention); and
  • healthcare environment (technology-based acute care promoted at the expense of preventive care)21.

Occurrence of an index stroke or TIA should prompt a systematic assessment for identification of vascular risk factors, patient education, plans for initiation of preventive intervention, goal setting and regular monitoring of the effectiveness of individual interventions. Patient empowerment and clarity in terms of leadership and responsibility for the individual management steps is paramount, and more needs to be done to bring clinical practice in line with the existing evidence-base.

Conflict of interest: Dr Mistri is the Trial Coordinator for the CHHIPS Study, an acute poststroke BP intervention study. Dr Fotherby has none declared.


  1. National Audit Office DoH Reducing Brain Damage: Faster access to better stroke care. 1-60. 16-11-2005
  2. Sandercock P, Gubitz G, Foley P et al. Antiplatelet therapy for acute ischaemic stroke. Cochrane Database of Systematic Reviews 2003;(Issue 2, ART No)
  3. Lewington S, Clarke R, Qizilbash N et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360(9349): 1903-1913
  4. Arima H, Chalmers J, Woodward M et al. Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial. J Hypertens 2006; 24(6):1201- 1208
  5. Rodgers A, MacMahon S, Gamble G, et al. Blood pressure and risk of stroke in patients with cerebrovascular disease. The United Kingdom Transient Ischaemic Attack Collaborative Group. BMJ 1996; 313(7050):147
  6. Irie K, Yamaguchi T, Minematsu K, Omae T. The J-curve phenomenon in stroke recurrence. Stroke 1993; 24(12):1844-1849
  7. Friday G, Alter M, Lai SM. Control of hypertension and risk of stroke recurrence. Stroke 2002; 33(11):2652-2657
  8. Ariesen MJ, Algra A, Warlow CP, Rothwell PM. Predictors of risk of intracerebral haemorrhage in patients with a history of TIA or minor ischaemic stroke. J Neurol Neurosurg Psychiatry Neurosurg Psychiatry 2006; 77(1):92-94
  9. Gueyffi er F, Boissel JP, Boutitie F et al. Effect of antihypertensive treatment in patients having already suffered from stroke. Gathering the evidence. The INDANA (INdividual Data ANalysis of Antihypertensive intervention trials) Project Collaborators. Stroke 1997; 28(12):2557-2562
  10. Rashid P, Leonardi-Bee J, Bath P. Blood pressure reduction and secondary prevention of stroke and other vascular events: a systematic review. Stroke 2003; 34(11): 2741-2748
  11. Robinson TG, Potter JF. Blood pressure in acute stroke. Age Ageing 2004; 33(1):6-12.
  12. PATS collaborating group. Post-stroke antihypertensive treatment study. A preliminary result. PATS Collaborating Group. Chin Med J (Engl) 1995; 108(9):710-717
  13. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358(9287):1033-1041
  14. 14.Yusuf S, Sleight P, Pogue J et al. Effects of an angiotensinconverting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med N Engl J Med 2000; 342(3):145-153
  15. Blood Pressure in Acute Stroke Collaboration (BASC). Interventions for deliberately altering blood pressure in acute stroke (Cochrane Review). Cochrane Database of Systemic Reviews 2004; 1(CD000039)
  16. Intercollegiate Stroke Working Party Royal College of Physicians National Clinical Guidelines for Stroke 2nd Edition. 1-146. 2006
  17. Sacco RL, Adams R, Albers G et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/ American Stroke Association Council on Stroke: cosponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Stroke 2006; 37(2):577-617
  18. Barer DH, Cruickshank JM, Ebrahim SB et al. Low dose beta blockade in acute stroke (“BEST” trial): an evaluation. Br Med J (Clin Res Ed) 1988; 296(6624):737-741
  19. Ahmed N, Nasman P, Wahlgren NG. Effect of intravenous nimodipine on blood pressure and outcome after acute stroke. Stroke 2000; 31(6):1250-1255
  20. Mant J, McManus RJ, Hare R. Applicability to primary care of national clinical guidelines on blood pressure lowering for people with stroke: cross sectional study. BMJ 2006; 332(7542):635-637
  21. Holloway RG Jr, Ringel SP. Narrowing the evidence-practice gap. Strengthening the link between research and clinical practice. Neurology Neurology 1998; 50(2):319-321

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read more ...

Privacy & Cookies Policy